| Iterum’s Antibiotic for Super Bugs Falls Short in Phase 3, Shares Sink | Frank Vinluan | 12/11/19 | National |
| Four New Drugs Are Around the Corner. Here’s What You Need to Know. | Ben Fidler | 08/15/19 | National |
| Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More | Ben Fidler | 06/14/19 | National |
| Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More | Ben Fidler | 04/19/19 | National |
| Achaogen Eyes Sale in Bankruptcy Auction a Year After FDA Approval | David Holley | 04/15/19 | San Francisco |
| Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel | Ben Fidler | 11/09/18 | National |
| Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections | Frank Vinluan | 10/22/18 | San Diego |
| Achaogen Restructures, Slashes Staff 28% as Antibiotic Launches | Frank Vinluan | 07/26/18 | San Francisco |
| Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On | Ben Fidler | 06/29/18 | National |
| Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More | Ben Fidler | 05/04/18 | National |
| Forge Therapeutics Raises $15M to Take on Drug-Resistant Superbugs | Frank Vinluan | 04/25/17 | San Diego |
| Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More | Alex Lash | 12/16/16 | National |
| With $32M, Boston Anti-Fungal Startup Morphs Into San Diego’s Cidara | Bruce V. Bigelow | 06/30/14 | San Diego |
| Achaogen Garners $72,000,000 New Round | VentureDeal | 03/12/14 | San Francisco |
| Achaogen Secures $18,905,707 New Funding | VentureDeal | 03/25/13 | San Francisco |
| With New Antibiotic in Hand, RQx Pharmaceuticals Looks for Partner | Bruce V. Bigelow | 11/28/12 | San Diego |
| Biotechies Need to Get Serious About Antibiotics, Where There is Money to Be Made | Luke Timmerman | 04/04/11 | National |
| Ouch for Arch: VC Bob Nelsen Says Ikaria Will March On After Withdrawing Big IPO | Luke Timmerman | 11/12/10 | Seattle |
| Tetraphase Shows What the $45M Was All About at Big Antibiotics Conference | Luke Timmerman | 09/15/10 | Boston |
| Tethys Pockets $33M, Achaogen’s Vision for Antibiotics, Genentech Strikes Out at FDA Panel, & More Bay Area Life Sciences News | Luke Timmerman | 07/23/10 | San Francisco |
| Achaogen, Flush with $56M, Seeks to Build Lasting Company with Potent Antibiotics | Luke Timmerman | 07/19/10 | San Francisco |
| The Top 10 Northern California Venture Deals of the Second Quarter—Two Ways | Wade Roush | 07/17/10 | San Francisco |
| Kristina Burow, Arch’s Rising Star in SF, Spots Big Ideas in Biotech, Cleantech | Luke Timmerman | 07/16/10 | San Francisco |
| Concur Goes Convertible, Frazier and Arch Back Achaogen, Lucid Commerce Gets Cash, & More Seattle-Area Deals News | Gregory T. Huang | 04/14/10 | Seattle |
| Sage Bionetworks On a Roll, Allon’s Foray into Alzheimer’s, Frazier Bets on Antibiotics, & More Seattle-Area Life Sciences News | Luke Timmerman | 04/08/10 | Seattle |
| Frazier, Arch Join $56M Antibiotic Deal | Luke Timmerman | 04/07/10 | Seattle |
| Achaogen Obtains $56,000,000 Series C Funding Round | VentureDeal | 04/07/10 | San Francisco |
| Inside a Life Sciences Industry Confab: Notes from Convergence | Ryan McBride | 06/17/09 | Boston |
| Indel Therapeutics Aims High With New Class of Antibiotics to Fight Hospital Infections | Luke Timmerman | 03/30/09 | Seattle |
| Follow-Up: Alnylam’s Biodefense Contract the Program’s Largest | Rebecca Zacks | 08/10/07 | Boston |
